Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
NCT02064985
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class
Conditions
Stable Coronary Heart Disease (CHD)
Interventions
DRUG:
Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
Sponsor
AstraZeneca